Serology Testing for COVID-19 at CDC
CDC has developed a laboratory test to help estimate how many people in the United States have been infected with SARS-CoV-2, the virus that causes COVID-19. Clinicians and researchers refer to this as a serology test, and many commercial laboratories call it an antibody test. CDC is using this serologic (antibody) test to evaluate the performance of commercial antibody tests. CDC will develop guidance for the use of antibody tests in clinical and public health settings.
An antibody test looks for the presence of antibodies, which are specific proteins made in response to infections. Antibodies are detected in the blood of people who are tested after infection; they show an immune response to the infection. Antibody test results are especially important for detecting previous infections in people who had few or no symptoms.
We do not know if the antibodies that result from SARS-CoV-2 infection will provide someone with protection (immunity) from getting infected again. If antibodies do provide immunity, we don’t know how much antibody is protective or how long protection might last. CDC scientists are currently conducting studies to answer these questions.
CDC’s serologic test has been designed and validated for surveillance and research purposes. It is designed to estimate the percentage of the U.S. population previously infected with the virus – information needed to guide the response to the pandemic and protect the public’s health.
The CDC test is not currently designed to test individuals who want to know if they have been previously infected with SARS-CoV-2. Commercial tests are available to provide test results to individuals.
CDC is evaluating the performance of commercial antibody tests
Commercially manufactured antibody tests check for SARS-CoV-2 antibodies in individuals and are available through healthcare providers and commercial laboratories. CDC is evaluating the performance of these tests in collaboration with the following federal organizations:
- Biomedical Advanced Research and Development Authority
- U.S. Food and Drug Administration (FDA)
- National Institutes of Health
- Department of Defense
- White House Office of Science and Technology Policy
Results from the initial federal evaluation are included in FDA’s EUA Authorized Serology Test Performanceexternal icon and will be updated as more tests are evaluated.
Read CDC’s interim guidelines for using antibody tests in clinical and public health settings.
About CDC’s serologic test
CDC’s serologic test is an ELISA-based testexternal icon to detect SARS-CoV-2 antibodies in serum or plasma components of blood. It uses purified SARS-CoV-2 S protein (no live virus) as antigen (designed by the Vaccine Research Centerexternal icon at the National Institutes of Health).
CDC’s serologic test is designed to detect antibodies produced in response to SARS-CoV-2 and minimize cross-reactivity to antibodies generated to other common coronaviruses that cause less severe illnesses, such as colds. However, potential cross-reactivity cannot be completely ruled out.
CDC’s serologic test has a specificity of greater than 99% and a sensitivity of 96% based on initial performance evaluations. It can be used to identify past SARS-CoV-2 infection in people who were infected at least 1 to 3 weeks previously.
CDC serology surveillance strategy
CDC has a strategy for using antibody testing as part of surveillance efforts to better understand how much of the U.S. population has been infected with SARS-CoV-2 and how the virus is spreading through the population over time.
Learn more about CDC’s COVID-19 serology surveillance strategy.